|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao J, Yang TT, Qiu XC, Yu B, Han JW, Fan
QY and Ma BA: Cloning and identification of microRNA from human
osteosarcoma cell line SOSP-9607. Ai Zheng. 26:561–565. 2007.(In
Chinese). PubMed/NCBI
|
|
6
|
Palmini G, Marini F and Brandi ML: What is
new in the mirna world regarding osteosarcoma and chondrosarcoma?
Molecules. 7:4172017. View Article : Google Scholar
|
|
7
|
Leichter AL, Sullivan MJ, Eccles MR and
Chatterjee A: MicroRNA expression patterns and signalling pathways
in the development and progression of childhood solid tumours. Mol
Cancer. 16:152017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen X, Yang TT, Qiu XC, Ji ZG, Li CX,
Long H, Zhou Y, Ma BA, Ma Q, Zhang X and Fan QY: Gene expression
profiles of human osteosarcoma cell sublines with different
pulmonary metastatic potentials. Cancer Biol Ther. 11:287–292.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu W, Lin Z, Zhuang Z and Liang X:
Expression profile of mammalian microRNAs in endometrioid
adenocarcinoma. Eur J Cancer Prev. 18:50–55. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rauhala HE, Jalava SE, Isotalo J, Bracken
H, Lehmusvaara S, Tammela TL, Oja H and Visakorpi T: MiR-193b is an
epigenetically regulated putative tumor suppressor in prostate
cancer. Int J Cancer. 127:1363–1372. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu C, Liu S, Fu H, Li S, Tie Y, Zhu J,
Xing R, Jin Y, Sun Z and Zheng X: MicroRNA-193b regulates
proliferation, migration and invasion in human hepatocellular
carcinoma cells. Eur J Cancer. 46:2828–2836. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li XF, Yan PJ and Shao ZM: Downregulation
of miR-193b contributes to enhance urokinase-type plasminogen
activator (uPA) expression and tumor progression and invasion in
human breast cancer. Oncogene. 28:3937–3948. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu H, Li S, Liu J and Ni B: MicroRNA-193b
modulates proliferation, migration, and invasion of non-small cell
lung cancer cells. Acta Biochim Biophys Sin (Shanghai). 44:424–430.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jancik S, Drabek J, Radzioch D and Hajduch
M: Clinical relevance of KRAS in human cancers. J Biomed
Biotechnol. 2010:1509602010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mao Q, Chen Z, Wang K, Xu R, Lu H and He
X: Prognostic role of high stathmin 1 expression in patients with
solid tumors: Evidence from a meta-analysis. Cell Physiol Biochem.
50:66–78. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao C, Li H, Wang L and Sun W: An
immunohistochemical study of stathmin 1 expression in osteosarcoma
shows an association with metastases and poor patient prognosis.
Med Sci Monit. 31:6070–6078. 2018. View Article : Google Scholar
|
|
17
|
Zhang H, He QY, Wang GC, Tong DK, Wang RK,
Ding WB, Li C, Wei Q, Ding C, Liu PZ, et al: MiR-422a inhibits
osteosarcoma proliferation by targeting BCL2L2 and KRAS. Biosci
Rep. 21:382018.
|
|
18
|
Swier L, Dzikiewicz-Krawczyk A, Winkle M,
van den Berg A and Kluiver J: Intricate crosstalk between MYC and
non-coding RNAs regulates hallmarks of cancer. Mol Oncol. 13:26–45.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang N, Wang X, Huo Q, Sun M, Cai C, Liu
Z, Hu G and Yang Q: MicroRNA-30a suppresses breast tumor growth and
metastasis by targeting metadherin. Oncogene. 33:3119–3128. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bai JX, Yan B, Zhao ZN, Xiao X, Qin WW,
Zhang R, Jia LT, Meng YL, Jin BQ, Fan DM, et al: Tamoxifen
represses miR-200 microRNAs and promotes epithelial-to-mesenchymal
transition by up-regulating c-Myc in endometrial carcinoma cell
lines. Endocrinology. 154:635–645. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang W, Xiao X, Chen X, Huo Y, Xi WJ, Lin
ZF, Zhang D, Li YF, Yang F, Wen WH, et al: Tumor-suppressive
miR-145 co-repressed by TCF4-β-catenin and PRC2 complexes forms
double-negative regulation loops with its negative regulators in
colorectal cancer. Int J Cancer. 142:308–321. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang YQ, Jiang DM, Hu SS, Zhao L, Wang L,
Yang MH, Ai ML, Jiang HJ, Han Y, Ding YQ and Wang S: SATB2-AS1
suppresses colorectal carcinoma aggressiveness by inhibiting
SATB2-Dependent snail transcription and epithelial-mesenchymal
transition. Cancer Res. 79:3542–3556. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang L, Zhang Y, Zhao L, Liu S, Yu S, Ma Y
and Sun G: MicroRNA-193b inhibits the proliferation, migration and
invasion of gastric cancer cells via targeting cyclin D1. Acta
Histochem. 118:323–330. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moore C, Parrish JK and Jedlicka P:
MiR-193b, downregulated in Ewing Sarcoma, targets the ErbB4
oncogene to inhibit anchorage-independent growth. PLoS One.
12:e01780282017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo F, Luo Y, Mu YF, Qin SL, Qi Y, Qiu YE
and Zhong M: MiR-193b directly targets STMN1 and inhibits the
malignant phenotype in colorectal cancer. Am J Cancer Res.
6:2463–2475. 2016.PubMed/NCBI
|
|
27
|
Jin X, Sun Y, Yang H, Li J, Yu S, Chang X,
Lu Z and Chen J: Deregulation of the MiR-193b-KRAS axis contributes
to impaired cell growth in pancreatic cancer. PLoS One.
10:e01255152015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhong Q, Wang T, Lu P, Zhang R, Zou J and
Yuan S: MiR-193b promotes cell proliferation by targeting Smad3 in
human glioma. J Neurosci Res. 92:619–626. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen J, Zhang X, Lentz C, Abi-Daoud M,
Paré GC, Yang X, Feilotter HE and Tron VA: MiR-193b regulates Mcl-1
in melanoma. Am J Pathol. 179:2162–2168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lenarduzzi M, Hui AB, Alajez NM, Shi W,
Williams J, Yue S, O'Sullivan B and Liu FF: MicroRNA-193b enhances
tumor progression via down regulation of neurofibromin 1. PLoS One.
8:e537652013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sampson VB, Yoo S, Kumar A, Vetter NS and
Kolb EA: MicroRNAs and potential targets in osteosarcoma: Review.
Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rubin CI and Atweh GF: The role of
stathmin in the regulation of the cell cycle. J Cell Biochem.
93:242–250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nie W, Xu MD, Gan L, Huang H, Xiu Q and Li
B: Overexpression of stathmin 1 is a poor prognostic biomarker in
non-small cell lung cancer. Lab Invest. 95:56–64. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Akhtar J, Wang Z, Jiang WP, Bi MM and
Zhang ZP: Stathmin overexpression identifies high risk for
lymphatic metastatic recurrence in pN0 esophageal squamous cell
carcinoma patients. J Gastroenterol Hepatol. 29:944–950. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baquero MT, Hanna JA, Neumeister V, Cheng
H, Molinaro AM, Harris LN and Rimm DL: Stathmin expression and its
relationship to microtubule-associated protein tau and outcome in
breast cancer. Cancer. 118:4660–4669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen YL, Uen YH, Li CF, Horng KC, Chen LR,
Wu WR, Tseng HY, Huang HY, Wu LC and Shiue YL: The E2F
transcription factor 1 transactives stathmin 1 in hepatocellular
carcinoma. Ann Surg Oncol. 20:4041–4054. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kang W, Tong JH, Chan AW, Lung RW, Chau
SL, Wong QW, Wong N, Yu J, Cheng AS and To KF: Stathmin1 plays
oncogenic role and is a target of microRNA-223 in gastric cancer.
PLoS One. 7:e339192012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lu Y, Liu C, Cheng H, Xu Y, Jiang J, Xu J,
Long J, Liu L and Yu X: Stathmin, interacting with Nf-κB, promotes
tumor growth and predicts poor prognosis of pancreatic cancer. Curr
Mol Med. 14:328–339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tan HT, Wu W, Ng YZ, Zhang X, Yan B, Ong
CW, Tan S, Salto-Tellez M, Hooi SC and Chung MC: Proteomic analysis
of colorectal cancer metastasis: Stathmin-1 revealed as a player in
cancer cell migration and prognostic marker. J Proteome Res.
11:1433–1445. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Biaoxue R, Xiguang C, Hua L and Shuanying
Y: Stathmin-Dependent molecular targeting therapy for malignant
tumor: The latest 5 years' discoveries and developments. J Transl
Med. 14:2792016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang HZ, Wang Y, Gao P, Lin F, Liu L, Yu
B, Ren JH, Zhao H and Wang R: Silencing stathmin gene expression by
survivin promoter-driven siRNA vector to reverse malignant
phenotype of tumor cells. Cancer Biol Ther. 5:1457–1461. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang Z, He R, Xia H, Wei Y and Wu S:
Knockdown of STMN1 enhances osteosarcoma cell chemosensitivity
through inhibition of autophagy. Oncol Lett. 13:3465–3470. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Feng T, Qiao G, Feng L, Qi W, Huang Y, Yao
Y and Shen Z: Stathmin is key in reversion of doxorubicin
resistance by arsenic trioxide in osteosarcoma cells. Mol Med Rep.
10:2985–2992. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang R, Dong K, Lin F, Wang X, Gao P, Wei
SH, Cheng SY and Zhang HZ: Inhibiting proliferation and enhancing
chemosensitivity to taxanes in osteosarcoma cells by RNA
interference-mediated downregulation of stathmin expression. Mol
Med. 13:567–575. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Karnoub AE and Weinberg RA: Ras oncogenes:
Split personalities. Nat Rev Mol Cell Biol. 9:517–531. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sun B, Wang F, Li M and Yang M:
Identifications of genetic differences between metastatic and
non-metastatic osteosarcoma samples based on bioinformatics
analysis. Med Oncol. 32:1532015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang S, Hou C, Li G, Zhong Y, Zhang J,
Guo X, Li B, Bi Z and Shao M: A single nucleotide polymorphism in
the 3′-untranslated region of the KRAS gene disrupts the
interaction with let-7a and enhances the metastatic potential of
osteosarcoma cells. Int J Mol Med. 38:919–926. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang X, Guo Q, Chen J and Chen Z:
Quercetin enhances cisplatin sensitivity of human osteosarcoma
cells by modulating microRNA-217-KRAS axis. Mol Cells. 38:638–642.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li Y, Liu H, Lai C, Du X, Su Z and Gao S:
The Lin28/let-7a/c-Myc pathway plays a role in non-muscle invasive
bladder cancer. Cell Tissue Res. 354:533–541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Akinyeke T, Matsumura S, Wang X, Wu Y,
Schalfer ED, Saxena A, Yan W, Logan SK and Li X: Metformin targets
c-MYC oncogene to prevent prostate cancer. Carcinogenesis.
34:2823–2832. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Dueck AC, Reinholz MM, Geiger XJ, Tenner
K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson
NE, et al: Impact of c-MYC protein expression on outcome of
patients with early-stage HER2+ breast cancer treated with adjuvant
trastuzumab NCCTG (alliance) N9831. Clin Cancer Res. 19:5798–5807.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li K, Chen MK, Situ J, Huang WT, Su ZL, He
D and Gao X: Role of co-expression of c-Myc, EZH2 and p27 in
prognosis of prostate cancer patients after surgery. Chin Med J
(Engl). 126:82–87. 2013.PubMed/NCBI
|
|
53
|
Liu Z, Jiang Y, Hou Y, Hu Y, Cao X, Tao Y,
Xu C, Liu S, Wang S, Wang L, et al: The IkB family member Bcl-3
stabilizes c-Myc in colorectal cancer. J Mol Cell Biol. 5:280–282.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Pello OM and Andres V: Role of C-MYC in
tumor-associated macrophages and cancer progression.
Oncoimmunology. 2:e229842013. View Article : Google Scholar : PubMed/NCBI
|
